AVTX

Avalo Therapeutics Inc

Add to Watchlist

Advanced Chart

4.060

-0.290(-6.670%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

4.400

Open

4.350

VWAP

4.23

Vol

35.99K

Mkt Cap

43.96M

Low

4.060

Amount

152.15K

EV/EBITDA(TTM)

Total Shares

1.03M

-87.45M

EV/OCF(TTM)

P/S(TTM)

72.82

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

0.00

-100%

Estimates Revision

Stock Price

Go Down

-48.99%

In Past 3 Month

7 Analyst Rating

720.94% Upside

Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 33.33 USD with a low forecast of 18.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

720.94% Upside

Current: 4.060

Low

18.00

Averages

33.33

High

48.00

720.94% Upside

Current: 4.060

Low

18.00

Averages

33.33

High

48.00

Stifel

Alex Thompson

Strong Buy

Initiates

$36

2025-03-25

Reason

Stifel

Alex Thompson

Price Target

$36

2025-03-25

Initiates

Strong Buy

Reason

Stifel analyst Alex Thompson initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $36 price target. The firm believes that hidradenitis suppurativa can become "one of the next large I&I markets where there is significant strategic interest" and that AVTX-009 is highly-derisked following proof-of-concept data from AbbVie's (ABBV) Lutikizumab, the analyst tells investors. With superior potency and selectivity, there's "also potential for superior efficacy as a credible upside scenario," the analyst argues.

Jefferies

Kambiz Yazdi

Strong Buy

Initiates

$23

2025-03-25

Reason

Jefferies

Kambiz Yazdi

Price Target

$23

2025-03-25

Initiates

Strong Buy

Reason

Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics with a Buy rating and $23 price target. Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo's lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-20

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-20

Reiterates

Hold

Reason

Piper Sandler

Yasmeen Rahimi

Buy

Initiates

$48

2025-02-28

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$48

2025-02-28

Initiates

Buy

Reason

BTIG

Julian Harrison

Strong Buy

Initiates

$40

2024-12-19

Reason

BTIG

Julian Harrison

Price Target

$40

2024-12-19

Initiates

Strong Buy

Reason

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics with a Buy rating and $40 price target. The firm sees the company's AVTX-009 as having best-in-class features that could support preferred positioning in several large indications. Avalo's lead efforts are in hidradenitis suppurativa, where BTIG continues to expect significant reward for more active treatment options, even after key IL-17A/F inhibitors are expected to be well-established, the analyst tells investors in a research note.

LUCID CAPITAL MARKETS

Dev Prasad

Strong Buy

Initiates

$24

2024-12-17

Reason

LUCID CAPITAL MARKETS

Dev Prasad

Price Target

$24

2024-12-17

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Avalo Therapeutics Inc (AVTX.O) is -0.85, compared to its 5-year average forward P/E of -2.64. For a more detailed relative valuation and DCF analysis to assess Avalo Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.64

Current PE

-0.85

Overvalued PE

-0.54

Undervalued PE

-4.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

224.77

Current PS

0.00

Overvalued PS

1593.40

Undervalued PS

-1143.85

Financials

Annual

Quarterly

FY2024Q4

YoY :

-66.37%

192.00K

Total Revenue

FY2024Q4

YoY :

+254.87%

-13.31M

Operating Profit

FY2024Q4

YoY :

+332.65%

-35.34M

Net Income after Tax

FY2024Q4

YoY :

-66.01%

-3.44

EPS - Diluted

FY2024Q4

YoY :

+443.89%

-15.04M

Free Cash Flow

FY2024Q4

YoY :

-60.57%

54.69

Gross Profit Margin - %

FY2024Q4

YoY :

+594.02%

-11.12K

FCF Margin - %

FY2024Q4

YoY :

+1186.69%

-18.41K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

12.8K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

100.0K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

69.7K

Volume

Months

6-9

2.9M

Volume

Months

0-12

80.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

12.8K

USD

Months

0-12

0.0

USD

Months

AVTX News & Events

Events Timeline

2025-03-26 (ET)

2025-03-26

07:06:53

Avalo Therapeutics appoints Heffernan as Chairman of the Board

2025-03-20 (ET)

2025-03-20

07:06:17

Avalo Therapeutics reports FY24 EPS ($20.91) vs ($113.58) last year

2025-01-02 (ET)

2025-01-02

06:12:33

Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer

News

5.0

03-26Newsfilter

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

6.5

03-25Benzinga

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

4.0

03-20Benzinga

HC Wainwright & Co. Reiterates Neutral on Avalo Therapeuticsto Neutral

People Also Watch

FPH

Five Point Holdings LLC

Candel Therapeutics Inc

Atea Pharmaceuticals Inc

Design Therapeutics Inc

Aldeyra Therapeutics Inc

2.180

USD

+0.93%

FAQ

What is Avalo Therapeutics Inc (AVTX) stock price today?

The current price of AVTX is 4.06 USD — it has decreased -6.67 % in the last trading day.

AVTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AVTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Avalo Therapeutics Inc (AVTX) stock price today?

What is Avalo Therapeutics Inc (AVTX)'s business?

What is the price predicton of AVTX Stock?

What is Avalo Therapeutics Inc (AVTX)'s revenue for the last quarter?

What is Avalo Therapeutics Inc (AVTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Avalo Therapeutics Inc (AVTX)'s fundamentals?

How many employees does Avalo Therapeutics Inc (AVTX). have?

What is Avalo Therapeutics Inc (AVTX) market cap?